摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-methyl-4-phenyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine | 54123-09-0

中文名称
——
中文别名
——
英文名称
9-methyl-4-phenyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine
英文别名
Ro 11-1464;9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine;13-Methyl-7-Phenyl-3-Thia-1,8,11,12-Tetraazatricyclo Trideca-2(6),4,7,10,12-Pentaene;13-methyl-7-phenyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
9-methyl-4-phenyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine化学式
CAS
54123-09-0
化学式
C15H12N4S
mdl
——
分子量
280.353
InChiKey
SIRFTOWPWPCSOP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    71.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A<br/>[FR] DÉRIVÉS THIÉNOTRIAZOLODIAZÉPINE ACTIFS SUR L'APO A
    申请人:DYBLY AG
    公开号:WO2010049466A1
    公开(公告)日:2010-05-06
    The invention relates to new thienotriazolodiazepine derivatives of the formula (1) wherein R1 is CH3, R2 is CH3 or -(CH2)n-R4 or -(CH2)n-O-R4 or -(CH2)n-S-R4 wherein n is 1, 2, 3 or 4 and R4 is CH3, CH2CH3 or CH2CH2OCH3, and R3 is hydrogen or -OCH2O- or -OCH2CH2O- connected to the ortho/meta position or meta/para position of the phenyl ring; or wherein R1 and R2 are hydrogen and R3 is -OCH2O- Or -OCH2CH2O- connected to the ortho/meta position or meta/para position of the phenyl ring; and pharmaceutically acceptable acid addition salts thereof. These compounds and pharmaceutical compositions containing them are useful in the treatment and prevention of atherosclerotic artery diseases, such as myocardial infarction and stroke, and of Alzheimer's disease.
    该发明涉及公式(1)的新噻唑三唑二氮杂环庚烷衍生物,其中R1为CH3,R2为CH3或-(CH2)n-R4或-(CH2)n-O-R4或-(CH2)n-S-R4,其中n为1、2、3或4,R4为CH3、CH2CH3或CH2CH2OCH3,R3为氢或-OCH2O-或-OCH2CH2O-连接到苯环的邻位/间位或间位/对位;或者R1和R2为氢,R3为-OCH2O-或-OCH2CH2O-连接到苯环的邻位/间位或间位/对位;以及其药学上可接受的酸盐。这些化合物及含有它们的药物组合物在治疗和预防动脉粥样硬化疾病,如心肌梗死和中风,以及阿尔茨海默病方面是有用的。
  • THIENOTRIAZOLODIAZEPINE DERIVATIVES ACTIVE ON APO A
    申请人:Kempen Herman
    公开号:US20110230460A1
    公开(公告)日:2011-09-22
    The invention relates to new thienotriazolodiazepine derivatives of the formula (1) wherein R 1 is CH 3 , R 2 is CH 3 or —(CH 2 ) n —R 4 or —(CH 2 ) n —O—R 4 or —(CH 2 ) n —S—R 4 wherein n is 1, 2, 3 or 4 and R 4 is CH 3 , CH 2 CH 3 or CH 2 CH 2 OCH 3 , and R 3 is hydrogen or —OCH 2 O— or —OCH 2 CH 2 O— connected to the ortho/meta position or meta/para position of the phenyl ring; or wherein R 1 and R 2 are hydrogen and R 3 is —OCH 2 O— Or —OCH 2 CH 2 O— connected to the ortho/meta position or meta/para position of the phenyl ring; and pharmaceutically acceptable acid addition salts thereof. These compounds and pharmaceutical compositions containing them are useful in the treatment and prevention of atherosclerotic artery diseases, such as myocardial infarction and stroke, and of Alzheimer's disease.
    本发明涉及以下式(1)的新的噻唑三唑二氮杂环衍生物,其中R1为CH3,R2为CH3或—(CH2)n—R4或—(CH2)n—O—R4或—(CH2)n—S—R4,其中n为1、2、3或4,R4为CH3、CH2CH3或CH2CH2OCH3,R3为氢或连接到苯环的邻/间位或间/对位的—OCH2O—或—OCH2CH2O—;或者R1和R2为氢,R3为连接到苯环的邻/间位或间/对位的—OCH2O—或—OCH2CH2O—;以及其药学上可接受的酸加成盐。这些化合物和含有它们的制药组合物在治疗和预防动脉粥样硬化性疾病,如心肌梗死和中风,以及阿尔茨海默病方面是有用的。
  • Compositions and therapeutic methods for the treatment of complement-associated diseases
    申请人:Resverlogix Corp.
    公开号:US10111885B2
    公开(公告)日:2018-10-30
    The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    本发明包括通过施用式 I 或式 II 的化合物,例如 2-(4-(2-羟基乙氧基)-3,5-二甲基苯基)-5,7-二甲氧基喹唑啉-4(3H)-酮或其药学上可接受的盐,调节哺乳动物体内的补体级联,治疗和/或预防与补体途径相关的疾病和失调的方法。
  • TAHARA T.; ARAKI K.; SHIROKI M.; MATSUO H.; MUNAKATA T., ARZNEIMITTEL-FORSCH., 1978, 28, NO 7, 1153-1158
    作者:TAHARA T.、 ARAKI K.、 SHIROKI M.、 MATSUO H.、 MUNAKATA T.
    DOI:——
    日期:——
  • USE OF A THIENOTRIAZOLODIAZEPINE TO INCREASE APOLIPOPROTEIN A-I LEVELS
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP0853480B1
    公开(公告)日:2003-01-08
查看更多

同类化合物

阿帕泛 贝帕泛 苯他西泮 环氯唑仑 溴替唑仑 氯噻西泮 司替帕泛 去甲氯噻西泮; 去甲基氯噻西泮; 5-(2-氯苯基)-7-乙基-1,3-二氢-2H-噻吩并[2,3-e][1,4]二氮杂卓-2-酮 伊拉帕泛 乙替唑仑 alpha-羟基依替唑仑 [(R,S)-4-(4-氯苯基)-2,3,9-三甲基-6H-1-硫杂-5,7,8,9a-四氮杂-环戊环[e]氮杂-6-基]-乙酸叔丁酯 N-(4-叔-丁基苯基)-6-(2-氯苯基)-1-甲基-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲酰胺 7-氯-5-(2-氯苯基)-1,3-二氢-2H-噻吩并-(2,3-e)-(1,4)-二氮杂卓-2-硫酮 7-乙基-5-苯基-3,4-二氢噻吩并[3,2-f][1,4]二氮杂卓-2-酮 7-乙基-5-(2-氟苯基)-1,3-二氢-2H-噻吩并[2,3-e]-1,4-二氮杂卓-2-酮 6-(2-氯苯基)-1-甲基-N-[4-(三氟甲基)苯基]-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 6-(2-氯苯基)-1-甲基-N-(1-甲基-2-苯基乙基)-7,10-二氢-4H-吡啶并[4',3':4,5]噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-9(8H)-甲硫代酰胺 5,6-二氢-5-甲基-6-氧代-4H-i咪唑并[1,5-a]噻吩并[2,3-f][1,4]二氮杂-3-羧酸1,1-二甲基乙酯 4-甲基-3,4-二氢-1H-噻吩并[2,3-E][1,4]二氮杂-2,5-二酮 4-(2-氯苯基)-N-(2-羟基乙基)-9-甲基-6H-噻吩并(3,2-f)(1,2,4)三唑并(4,3-a)(1,4)二氮杂卓-2-丙酰胺 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸甲酯 4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-丙酸 4-(2-氯苯基)-9-甲基-2-(4-吗啉-4-基-4-羰基丁基)-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓 3-噻丁烷酮,2-氯-2-(1-甲基乙基)- 3-[4-(2-氯苯基)-9-甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂卓-2-基]-2-丙炔-1-醇 2-((6R)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F]的[1,2,4 (S)-4-(4-氯苯基)-N-(4-羟基苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-乙酰胺 (S)-2-(4-(4-氯苯基)-2-(羟甲基)-3,9-二甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3]-A][1,4]二氮杂卓-6-基)乙酸甲酯 (S)-(+)-2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)乙酸叔丁酯 (-)-JQ-1; (R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 (+)-JQ1羧酸 10-Amino-4H-2,5-dihydrothieno[3,4-b][1,5]benzodiazepine ethyl 5,6-dihydro-6-thioxo-4H-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate ethyl 5,6-dihydro-6-oxo-4H-imidazo[1,5-a]thieno[2,3-f][1,4]diazepine-3-carboxylate 2-hexyl-4-(4-methylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[ 4,3-a][1,4]diazepine 2-hexyl-4-(2,4-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 2-hexyl-4-(3-methylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 7-hexyl-5-(2,5-dimethylphenyl)-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 2-hexyl-4-(2,5-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 2-hexyl-4-(3,4,5-trimethoxyphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 7-hexyl-5-(4-methylphenyl)-1,3-dihydro-2H-thieno[2,3-e]-1,4-diazepin-2-one 7-(2,3-dimethylphenyl)-4-hexyl-13-methyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaene 2-hexyl-4-(3,4-dimethylphenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 1-(4-((4-ethylpiperazine-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepine-4-yl)phenyl)urea 5,6-dihydro-6-N,N-dimethylhydrazino-4H-pyrrolo<1,2-a>thieno<3,2-f><1,4>diazepin-4-one 2-(2-acetylhydrazino)-7-chloro-5-(2,6-difluorophenyl)-3H-thieno[2,3-e]-1,4-diazepine (S)-N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide